The use of therapeutic oligonucleotides (TONs) has become a major alternative to treat
disease thanks to recent advances in oligonucleotide synthesis and delivery technologies.
Cancer is the result of progressive and accumulative changes in the cell genome and the
host physiology that lead to uncontrolled growth and proliferation, metabolic changes,
immune evasion, and ultimately metastasis and death. The present review focuses on
oligonucleotide-based cancer therapies that have reached clinical trials. Although very …